Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population

Byung-Joo Ham, Boung Chul Lee, Jong W. Paik, Rhee H. Kang, Myoung J. Choi, Ihn Geun Choi, Min-Soo Lee

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Tryptophan hydroxylase-1 (TPH1) is the rate-limiting enzyme in serotonin biosynthesis, and selective serotonin reuptake inhibitors (SSRIs) exert their activity enhancing the general serotonergic tone. Citalopram is the most selective SSRI, with little or no affinity for a variety of receptor types. The goal of this study was to investigate whether the A218C polymorphism of the TPH1 gene is associated with the citalopram antidepressant response in subjects with major depressive disorder (MDD). All of the patients were evaluated using the 21-item Hamilton Depression Rating Scale before beginning and after 8 weeks of citalopram treatment. Genotyping was performed with the polymerase chain reaction. The remission rate to citalopram treatment was worse in MDD subjects with the TPH1 A/A and A/C genotypes than in those with the TPH1 C/C genotype. Our results suggest that the A218C polymorphism of the TPH1 gene serves as a modulator of antidepressant activity, especially in terms of treatment remission.

Original languageEnglish
Pages (from-to)104-107
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume31
Issue number1
DOIs
Publication statusPublished - 2007 Jan 30

Fingerprint

Tryptophan Hydroxylase
Citalopram
Antidepressive Agents
Population
Genes
Major Depressive Disorder
Serotonin Uptake Inhibitors
Genotype
Serotonin
Therapeutics
Depression
Polymerase Chain Reaction
Enzymes

Keywords

  • Citalopram
  • Major depressive disorder
  • Polymorphism
  • Tryptophan hydroxylase

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. / Ham, Byung-Joo; Lee, Boung Chul; Paik, Jong W.; Kang, Rhee H.; Choi, Myoung J.; Choi, Ihn Geun; Lee, Min-Soo.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 31, No. 1, 30.01.2007, p. 104-107.

Research output: Contribution to journalArticle

Ham, Byung-Joo ; Lee, Boung Chul ; Paik, Jong W. ; Kang, Rhee H. ; Choi, Myoung J. ; Choi, Ihn Geun ; Lee, Min-Soo. / Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2007 ; Vol. 31, No. 1. pp. 104-107.
@article{76026dc65e304ff787ba29fa9c3b509a,
title = "Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population",
abstract = "Tryptophan hydroxylase-1 (TPH1) is the rate-limiting enzyme in serotonin biosynthesis, and selective serotonin reuptake inhibitors (SSRIs) exert their activity enhancing the general serotonergic tone. Citalopram is the most selective SSRI, with little or no affinity for a variety of receptor types. The goal of this study was to investigate whether the A218C polymorphism of the TPH1 gene is associated with the citalopram antidepressant response in subjects with major depressive disorder (MDD). All of the patients were evaluated using the 21-item Hamilton Depression Rating Scale before beginning and after 8 weeks of citalopram treatment. Genotyping was performed with the polymerase chain reaction. The remission rate to citalopram treatment was worse in MDD subjects with the TPH1 A/A and A/C genotypes than in those with the TPH1 C/C genotype. Our results suggest that the A218C polymorphism of the TPH1 gene serves as a modulator of antidepressant activity, especially in terms of treatment remission.",
keywords = "Citalopram, Major depressive disorder, Polymorphism, Tryptophan hydroxylase",
author = "Byung-Joo Ham and Lee, {Boung Chul} and Paik, {Jong W.} and Kang, {Rhee H.} and Choi, {Myoung J.} and Choi, {Ihn Geun} and Min-Soo Lee",
year = "2007",
month = "1",
day = "30",
doi = "10.1016/j.pnpbp.2006.08.001",
language = "English",
volume = "31",
pages = "104--107",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population

AU - Ham, Byung-Joo

AU - Lee, Boung Chul

AU - Paik, Jong W.

AU - Kang, Rhee H.

AU - Choi, Myoung J.

AU - Choi, Ihn Geun

AU - Lee, Min-Soo

PY - 2007/1/30

Y1 - 2007/1/30

N2 - Tryptophan hydroxylase-1 (TPH1) is the rate-limiting enzyme in serotonin biosynthesis, and selective serotonin reuptake inhibitors (SSRIs) exert their activity enhancing the general serotonergic tone. Citalopram is the most selective SSRI, with little or no affinity for a variety of receptor types. The goal of this study was to investigate whether the A218C polymorphism of the TPH1 gene is associated with the citalopram antidepressant response in subjects with major depressive disorder (MDD). All of the patients were evaluated using the 21-item Hamilton Depression Rating Scale before beginning and after 8 weeks of citalopram treatment. Genotyping was performed with the polymerase chain reaction. The remission rate to citalopram treatment was worse in MDD subjects with the TPH1 A/A and A/C genotypes than in those with the TPH1 C/C genotype. Our results suggest that the A218C polymorphism of the TPH1 gene serves as a modulator of antidepressant activity, especially in terms of treatment remission.

AB - Tryptophan hydroxylase-1 (TPH1) is the rate-limiting enzyme in serotonin biosynthesis, and selective serotonin reuptake inhibitors (SSRIs) exert their activity enhancing the general serotonergic tone. Citalopram is the most selective SSRI, with little or no affinity for a variety of receptor types. The goal of this study was to investigate whether the A218C polymorphism of the TPH1 gene is associated with the citalopram antidepressant response in subjects with major depressive disorder (MDD). All of the patients were evaluated using the 21-item Hamilton Depression Rating Scale before beginning and after 8 weeks of citalopram treatment. Genotyping was performed with the polymerase chain reaction. The remission rate to citalopram treatment was worse in MDD subjects with the TPH1 A/A and A/C genotypes than in those with the TPH1 C/C genotype. Our results suggest that the A218C polymorphism of the TPH1 gene serves as a modulator of antidepressant activity, especially in terms of treatment remission.

KW - Citalopram

KW - Major depressive disorder

KW - Polymorphism

KW - Tryptophan hydroxylase

UR - http://www.scopus.com/inward/record.url?scp=33845760846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845760846&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2006.08.001

DO - 10.1016/j.pnpbp.2006.08.001

M3 - Article

VL - 31

SP - 104

EP - 107

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -